Gestational diabetes mellitus (GDM) is one of the most common complications during pregnancy. The incidence of gestational diabetes mellitus increases year by year. Its pathogenesis may be related to insulin resistance, and its diagnostic criteria are more stringent than common type 2 diabetes. The management of gestational diabetes requires diet, exercise, drug therapy, blood glucose monitoring and diabetes knowledge education. Diet and exercise therapy are the main treatment measures, but for poor glycemic control on this basis, drugs are an essential treatment plan. Currently available drugs for pregnancy include insulin, metformin and glyburide. In addition to these traditional drugs, probiotics, inositol, insulin-like growth factor-1 and vitamin D have been found to be safer drugs, but the effectiveness of these drugs needs further study. The purpose of this paper is to review various gestational diabetes drugs, to help us fully understand the advantages and disadvantages of various drugs, better intervention in the occurrence and development of the disease.

Zhengwei Zhang, Ningxia Yuan. Gestational Diabetes Mellitus: Treatment Progress. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 4: 54-59. https://doi.org/10.25236/IJFM.2023.050409.

[1] Sweeting, A., Wong, J., Murphy, H.R., and Ross, G.P. (2022) A Clinical Update on Gestational Diabetes Mellitus. Endocrine reviews, 43, 763-793.

[2] Gunderson, E.P., Sun, B., Catov, J.M., Carnethon, M., Lewis, C.E., Allen, N.B., et al. (2021) Gestational Diabetes History and Glucose Tolerance After Pregnancy Associated With Coronary Artery Calcium in Women During Midlife: The CARDIA Study. Circulation, 143, 974-987.

[3] American Diabetes Association. (2020). Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43(Suppl 1),S183-S192.

[4] Yu, F., Lv, L., Liang, Z., Wang, Y., Wen, J., Lin, X., et al. (2014) Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study. J Clin Endocrinol Metab, 99, 4674-4682.

[5] Voormolen, D.N., DeVries, J.H., Sanson, R.M.E., Heringa, M.P., de Valk, H.W., Kok, M., et al. (2018) Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. Diabetes Obes Metab, 20, 1894-1902.

[6] Yamamoto, J.M., Kellett, J.E., Balsells, M., García-Patterson, A., Hadar, E., Solà, I., et al. (2018) Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight. Diabetes care, 41, 1346-1361.

[7] Almenning, I., Rieber-Mohn, A., Lundgren, K.M., Shetelig Lovvik, T., Garnaes, K.K., and Moholdt, T. (2015) Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study. PLoS One, 10, e0138793.

[8] Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R., Moore, M.P., and Mi, G.T.I. (2008) Metformin versus insulin for the treatment of gestational diabetes. The New England journal of medicine, 358, 2003-2015.

[9] Landi, S.N., Radke, S., Engel, S.M., Boggess, K., Stürmer, T., Howe, A.S., et al. (2019) Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA pediatrics, 173, 160-168.

[10] Tarry-Adkins, J.L., Aiken, C.E., and Ozanne, S.E. (2019) Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS medicine, 16, e1002848.

[11] Dodd, J.M., Louise, J., Deussen, A.R., Grivell, R.M., Dekker, G., McPhee, A.J., et al. (2019) Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology, 7, 15-24.

[12] Hebert, M.F., Ma, X., Naraharisetti, S.B., Krudys, K.M., Umans, J.G., Hankins, G.D., et al. (2009) Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther, 85, 607-614.

[13] Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., and Corcoy, R. (2015) Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ (Clinical research ed.), 350, h102.

[14] Sénat, M.V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., et al. (2018) Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Jama, 319, 1773-1780.

[15] Pellonpera, O., Mokkala, K., Houttu, N., Vahlberg, T., Koivuniemi, E., Tertti, K., et al. (2019) Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Diabetes care, 42, 1009-1017.

[16] Santamaria, A., Di Benedetto, A., Petrella, E., Pintaudi, B., Corrado, F., D'Anna, R., et al. (2016) Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med, 29, 3234-3237.

[17] Farren, M., Daly, N., McKeating, A., Kinsley, B., Turner, M.J., and Daly, S. (2017) The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes care, 40, 759-763.

[18] Rojas-Rodriguez, R., Ziegler, R., DeSouza, T., Majid, S., Madore, A.S., Amir, N., et al. (2020) PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans. Sci Transl Med, 12.

[19] Holick, M.F. (2007) Vitamin D deficiency. The New England journal of medicine, 357, 266-281.